MedTrace Logo

Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection

NCT00790998 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1497

Last updated 2018-01-31

No results posted yet for this study

Summary

This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes river blindness. Subjects participating in the study will be randomly assigned (by a 2 to1 ratio) to receive one orally-administered dose of either moxidectin or ivermectin.

Conditions

  • Onchocerciasis

Interventions

DRUG

Moxidectin

Single dose of moxidectin 2 mg oral tablet x 4

DRUG

Ivermectin

Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4

Sponsors & Collaborators

Principal Investigators

  • Special Programme for Research and Training in Tropical Diseases (TDR) · World Health Organization

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-02-29
Completion
2012-05-31

Countries

  • Democratic Republic of the Congo
  • Ghana
  • Liberia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790998 on ClinicalTrials.gov